Ser914

Site Information
SVRsKVGstENIKHQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 1210622

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ) , mass spectrometry (in vitro) ( 12 ) , phospho-antibody ( 1 , 12 , 21 ) , western blotting ( 1 , 12 , 21 )
Disease tissue studied:	anthrax infection ( 19 ) , neuroblastoma ( 17 ) , melanoma skin cancer ( 42 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 4 , 5 , 9 ) , 'brain, cerebral cortex' ( 24 ) , 'fat, brown' ( 20 ) , 'heart, ventricle' ( 12 ) , 3T3 (fibroblast) ( 43 ) , 3T3-L1 (fibroblast) ( 32 , 44 , 45 , 46 ) , brain ( 15 , 20 , 23 ) , C2C12 (myoblast) ( 38 , 39 , 40 , 41 ) , fibroblast-lung ( 33 , 34 , 35 , 36 , 37 ) , heart ( 10 , 20 , 21 ) , kidney ( 20 ) , liver ( 2 , 8 , 14 , 20 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ) , liver [leptin (mouse), homozygous knockout] ( 14 ) , lung ( 20 ) , macrophage-bone marrow ( 22 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 22 ) , macrophage-peritoneum ( 13 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 11 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 11 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 16 ) , MEF (fibroblast) ( 11 , 13 ) , myocyte-heart ( 1 , 12 ) , N1E-115 (neuron) ( 17 ) , pancreas ( 20 ) , RAW 264.7 (macrophage) ( 6 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 42 ) , spleen ( 19 , 20 ) , T lymphocyte-spleen ( 18 ) , testis ( 20 )

Upstream Regulation
Regulatory protein:	leptin (mouse) ( 14 ) , RIPK3 (mouse) ( 13 )
Putative in vivo kinases:	AMPKA1 (mouse) ( 12 ) , MARK4 (mouse) ( 1 )
Kinases, in vitro:	AMPKA1 (human) ( 12 )
Putative upstream phosphatases:	PPP1CA (mouse) ( 21 ) , PPP2CA (mouse) ( 21 )
Treatments:	acadesine ( 12 ) , insulin ( 9 ) , LY294002 ( 9 ) , myocardial infarction ( 1 ) , NAG-thiazoline ( 43 ) , okadaic_acid ( 43 ) , PUGNAc ( 43 ) , refeeding ( 14 )

Downstream Regulation
Effects of modification on biological processes:	cytoskeletal reorganization ( 1 , 12 )

Disease / Diagnostics Relevance
Relevant diseases:	hypertrophic cardiomyopathy ( 21 )

References
1	Yu X, et al. (2021) MARK4 controls ischaemic heart failure through microtubule detyrosination. Nature 594, 560-565 34040253 Curated Info
2	Robles MS, Humphrey SJ, Mann M (2017) Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab 25, 118-127 27818261 Curated Info
3	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
4	Minard AY, et al. (2016) mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep 17, 29-36 27681418 Curated Info
5	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
6	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86 23567750 Curated Info
9	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
10	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
11	Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3 23429704 Curated Info
12	Fassett JT, et al. (2013) AMPK attenuates microtubule proliferation in cardiac hypertrophy. Am J Physiol Heart Circ Physiol 304, H749-58 23316058 Curated Info
13	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
14	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
15	Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9 22807455 Curated Info
16	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
17	Wang Y, et al. (2011) Spatial phosphoprotein profiling reveals a compartmentalized extracellular signal-regulated kinase switch governing neurite growth and retraction. J Biol Chem 286, 18190-201 21454597 Curated Info
18	Navarro MN, et al. (2011) Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 12, 352-61 21399638 Curated Info
19	Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 21189417 Curated Info
20	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
21	Cheng G, et al. (2010) Basis for MAP4 Dephosphorylation-related Microtubule Network Densification in Pressure Overload Cardiac Hypertrophy. J Biol Chem 285, 38125-40 20889984 Curated Info
22	Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371 20531401 Curated Info
23	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
24	Tweedie-Cullen RY, Reck JM, Mansuy IM (2009) Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 8, 4966-82 19737024 Curated Info
25	Guo A (2009) CST Curation Set: 7827; Year: 2009; Biosample/Treatment: tissue, liver(STK11)/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
26	Guo A (2009) CST Curation Set: 7822; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
27	Guo A (2009) CST Curation Set: 7825; Year: 2009; Biosample/Treatment: tissue, liver(STK11)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
28	Guo A (2009) CST Curation Set: 7826; Year: 2009; Biosample/Treatment: tissue, liver(STK11)/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
29	Guo A (2009) CST Curation Set: 7821; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
30	Guo A (2009) CST Curation Set: 7819; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
31	Guo A (2009) CST Curation Set: 7820; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
32	Guo A (2009) CST Curation Set: 7448; Year: 2009; Biosample/Treatment: cell line, 3T3-L1/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
33	Guo A (2009) CST Curation Set: 6407; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
34	Guo A (2009) CST Curation Set: 6405; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
35	Guo A (2009) CST Curation Set: 6404; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
36	Guo A (2009) CST Curation Set: 6406; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
37	Guo A (2009) CST Curation Set: 6403; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
38	Guo A (2009) CST Curation Set: 6167; Year: 2009; Biosample/Treatment: cell line, C2C12/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
39	Guo A (2009) CST Curation Set: 6166; Year: 2009; Biosample/Treatment: cell line, C2C12/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
40	Guo A (2009) CST Curation Set: 6164; Year: 2009; Biosample/Treatment: cell line, C2C12/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
41	Guo A (2009) CST Curation Set: 6165; Year: 2009; Biosample/Treatment: cell line, C2C12/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
42	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
43	Wang Z, Gucek M, Hart GW (2008) Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc Natl Acad Sci U S A 105, 13793-8 18779572 Curated Info
44	Possemato A (2008) CST Curation Set: 4744; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
45	Possemato A (2008) CST Curation Set: 4745; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
46	Possemato A (2008) CST Curation Set: 4747; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info